CKD (Chronic Kidney Disease) Stage 5T, Diabetes Mellitus, Simultaneous Pancreas Kidney Transplantation
Conditions
Keywords
Grafalon ATG SPK
Brief summary
A single-centre, prospective, observational study to evaluate the safety and efficacy of Polyclonal Antibodies in simultaneous Pancreas Kidney Transplant recipients.
Detailed description
Polyclonal antibody mainly contains Antit-Tlymphocyte globulins(Grafalon) and Anti-thymocyte globulins(ATG). To investigate the efficacy and safety of polyclonal antibodies induction regimen using Grafalon compared with ATG in de novo simultaneous pancreas kidney transplant recipients. The primary analysis of this study is to demonstrate the non-inferiority of the two regimens with regard to efficacy, defined as failure rate. The secondary objective of the study is the assessment of safety and further efficacy parameters in terms of incidence of acute rejections, graft/patient survival, DGF(delayed graft function), pancreas function and renal function
Interventions
DRUGAnti-Tlymphocyte Globulins
Induction therapy regimen in simultaneous pancreas kidney transplantation
DRUGAnti-Thymocyte Globulins
Induction therapy regimen in simultaneous pancreas kidney transplantation
Sponsors
Tianjin First Central Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. with end-stage,diabetic nephropathy(type1or 2) 2. Patients scheduled to undergo SPK with compatible ABO blood type. 3. Peak PRA \<50% 4. Females of childbearing potential must have a negative pregnancy test within 48hrs prior to randomization and reliable methods of contraception should be started 4 weeks prior to and during the whole study. 5. Patient must have signed the Patient Informed Consent Form. 6. Patient must receive a primary simultaneous pancreas/kidney (SPK) cadaveric transplant, with either intestinal or bladder and either portal or systemic venous drainages.
Exclusion criteria
1. Patient is pregnant or breastfeeding. 2. Patient has a positive T-cell crossmatch on the most recent serum specimen. 3. Patient is known for active liver disease or has significant liver disease, defined by ASAT and ALAT serum levels greater than 3 times the upper limit of normal. 4. Patient has malignancy or history of malignancy, with the exception of adequately treated localised squamous cell or basal cell carcinoma, without recurrence. 5. Patient has been included in another clinical trial protocol for any investigational drug within 4 weeks prior to randomisation. 6. Patient has any form of substance abuse, psychiatric disorder or condition, which, in the opinion of the investigator, may invalidate communication. 7. Patient receives a SPK transplant from a living donor, or receives segmental pancreatic transplant, or a previous kidney transplant alone. 8. Donor is older than 55 years of age 9. patients with bacterial, viral or mycotic infections which are not under therapeutically control
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and severity of adverse event | up to 3 months post-transplantation | Incidence of patient's death,graft loss,acute rejection |
Countries
China
Outcome results
None listed